Modified Radical Mastectomy — Procedure Guide, Recovery & Risks | MyMedicPlus

Modified radical mastectomy (MRM) removes the entire breast — including the nipple-areolar complex and overlying skin — together with axillary lymph nodes at levels I and II, while preserving the pectoralis major and minor muscles. It is one of the most widely performed oncological breast operations globally, offering both locoregional disease control and definitive pathological nodal staging in a single operative procedure. MRM replaced the Halsted radical mastectomy (which removed both pectoral muscles) as the standard operation in the 1970s following Auchincloss and Patey's randomised trials demonstrating equivalent survival outcomes with significantly less morbidity. Preservation of the pectoralis major — the key distinction from radical mastectomy — maintains shoulder girdle strength, reduces arm and shoulder disability, and critically enables immediate or delayed breast reconstruction using tissue expanders, direct-to-implant implants, or autologous tissue flaps (TRAM, DIEP, latissimus dorsi). MRM takes approximately 2–3 hours under general anaesthesia and remains the standard surgical option for locally advanced breast cancer, node-positive disease, or when breast-conserving surgery is contraindicated or declined by the patient following shared multidisciplinary decision-making.

This treatment represents an important component of modern medical management, supported by clinical evidence from multiple randomised controlled trials and systematic reviews. Treatment protocols are continually refined based on emerging evidence to optimise patient outcomes while minimising treatment burden.

Patient suitability is assessed through a structured multidisciplinary evaluation incorporating clinical history, physical examination findings, and results of relevant investigations. Treatment planning considers the full clinical context including disease characteristics, patient comorbidities, functional status, and individual treatment goals to ensure the most appropriate therapeutic approach is selected for each patient.

MRM is indicated for locally advanced breast cancer (T3–T4), tumours too large relative to breast volume for adequate margin-clear lumpectomy, inflammatory breast cancer following neoadjuvant chemotherapy, multicentric or multifocal disease not amenable to wide local excision, ipsilateral recurrence after prior breast-conserving surgery and radiotherapy, and patients who prefer mastectomy over conservation after full informed discussion. Contraindications include inability to tolerate general anaesthesia, active infection at the surgical site, and prior chest wall irradiation impairing wound healing. Additional indications include node-positive disease on sentinel node biopsy requiring axillary dissection at the same operative setting, BRCA1/2 pathogenic variant carriers electing risk-reduction bilateral mastectomy, and patients with persistently positive margins after repeated re-excision who would require extensive breast tissue removal. Operable T1–T2 tumours in patients declining radiotherapy — which is required after lumpectomy — may also proceed to MRM. All decisions are individualised through multidisciplinary breast team discussion involving the oncological surgeon, medical oncologist, radiation oncologist, pathologist, radiologist, breast care nurse specialist, and reconstructive surgeon, with patient preferences and quality-of-life priorities central to the decision.

After general anaesthesia, the patient is positioned supine with the ipsilateral arm abducted at 90 degrees on an arm board to provide full access to the breast and axilla. An elliptical skin incision incorporating the nipple-areolar complex and any prior biopsy scar is marked and executed with a scalpel. Superior and inferior skin flaps — 5–8 mm thick containing a thin layer of subcutaneous fat — are raised bluntly and with diathermy across the full breast footprint from the clavicle superiorly to the inframammary fold inferiorly, and from the sternal edge medially to the anterior axillary line laterally. All breast glandular tissue is excised en bloc from the pectoralis major fascia, which is preserved. Axillary dissection proceeds by entering the axillary space between the pectoralis minor and the chest wall; the axillary fat pad containing level I and II nodes is dissected free from its boundaries. The long thoracic nerve (running along the chest wall to serratus anterior) and the thoracodorsal nerve and vessels (entering the posterior axillary wall to supply latissimus dorsi) are identified and meticulously preserved; injury to either causes serratus weakness (winging scapula) or inability to use latissimus for reconstruction, respectively. The axillary vein superiorly forms the upper boundary of dissection. A minimum of 10 lymph nodes is required for adequate staging. Two closed suction drains — one in the axilla and one beneath the skin flap — are placed before layered wound closure with absorbable sutures. Immediate reconstruction by a plastic surgeon may extend total operative time to 4–6 hours.

MRM provides excellent locoregional tumour control with local recurrence rates under 5% for appropriately staged disease treated with guideline-directed adjuvant systemic therapy. A critical benefit of MRM is that axillary lymph node dissection at the same operative sitting provides definitive pathological nodal staging — the precise number of positive nodes, extranodal extension, and node ratio — that directly guides all subsequent oncological treatment decisions including chemotherapy regimen selection, post-mastectomy radiotherapy indication, and endocrine therapy duration. Preservation of the pectoralis major maintains shoulder girdle function and enables comprehensive reconstruction options. Five-year overall survival is 75–85% for Stage II and 50–65% for Stage III disease with modern adjuvant systemic and targeted therapy regimens including pertuzumab and trastuzumab for HER2-positive disease and CDK4/6 inhibitors for hormone receptor-positive advanced disease. Immediate breast reconstruction after MRM achieves high patient-reported satisfaction with cosmetic and psychological outcomes in over 80% of cases, dramatically improving body image and quality of life compared with mastectomy without reconstruction.

Lymphoedema of the ipsilateral arm is the most significant long-term morbidity, affecting 15–25% of patients after full axillary dissection versus under 5% after sentinel node biopsy alone. Seroma formation in the axillary dead space occurs in 30–50% and is managed by repeated aspiration. Wound infection affects approximately 5–10%. Intercostobrachial nerve damage during axillary dissection causes numbness or dysaesthesia along the medial upper arm in up to 70% of patients, improving gradually over time. Chest wall skin flap necrosis occurs in smokers or after excessive flap tension. Shoulder stiffness and reduced range of motion are mitigated by early physiotherapy beginning at one week. Haematoma requiring surgical evacuation occurs in under 2%. Immediate reconstruction adds the risks of implant-related complications including capsular contracture and implant infection.

Closed suction drains remain in situ for 1–2 weeks after MRM, removed in clinic when daily output falls consistently below 30 mL for 24 hours. Hospital stay is typically 2–4 days; patients with immediate reconstruction may stay 3–5 days. Pain is managed with regular paracetamol, NSAIDs, and short-course opioids as required. A graduated shoulder physiotherapy programme — beginning with pendulum exercises and progressive arm elevation from day 7 — aims to restore full shoulder range of motion by 6–8 weeks and is essential for preventing frozen shoulder and reducing lymphoedema risk. Heavy lifting above 2–3 kg and strenuous arm activity are avoided for 4–6 weeks. Adjuvant chemotherapy begins 3–4 weeks post-operatively once wound healing is confirmed; post-mastectomy radiotherapy commences 4–6 weeks after chemotherapy completion, or 6–8 weeks after surgery if chemotherapy is not required. Lymphoedema precautions — avoiding venepuncture, blood pressure measurement, and tight jewellery or garments on the operated arm — are advised lifelong to protect the compromised axillary lymphatic drainage. A compression sleeve prescribed by the lymphoedema nurse is worn during air travel and high-exertion activities. Patients with immediate reconstruction follow an additional plastic surgery protocol as directed. Scar massage with silicone gel from 6 weeks accelerates wound maturation and softening over 6–12 months.